Tradestie Institutional Equity Comparison Engine

CING vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CING N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin 0.0% vs -485.4% ยท YoY +0.0% vs +408.6%
Momentum & Technical Winner SRZN
1Y +36.4% vs +132.4% ยท 52W Pos 18% vs 70%
Options & Structure Winner SRZN
BREAKDOWN (16th %ile IV) vs CONSOLIDATION (5th %ile IV)
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
1M Return +9.17%
1Y Return +36.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$30.16
-6.68% 1D
Market Cap $602.5M
1M Return +26.51%
1Y Return +132.36%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CING +36.39% SRZN +132.36% Spread: +95.97 pp (SRZN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CING TTM Op. Margin: 0.0% SRZN TTM Op. Margin: -485.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs SRZN. Trailing 12-month operating profitability (CING 0.0% vs SRZN -485.4%) and valuation multiples (CING N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CING (2) vs SRZN (5)
Institutional Metric CING SRZN Criterion Row Winner
Market Capitalization Scale $62.5M $602.5M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability 0.0% -485.4% Higher Margin CING
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -198.7% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 18% ($3โ€“$12) 70% ($12โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.13ฮฒ ยท 117% Vol 1.28ฮฒ ยท 70% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 33.2 / 100 (SELL) Higher Composite CING

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CING vs SRZN Buy Guide
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CING nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.